71 results on '"Axitinib"'
Search Results
2. Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
3. Tumor hypoxia and role of hypoxia-inducible factor in oral cancer
4. First-line dual immune checkpoint inhibitor therapies versus combination therapies comprising immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced renal cell carcinoma: a comparative analysis of the effectiveness using real-world data
5. Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib
6. Using three-dimensional model-based tumour volume change to predict the symptom improvement in patients with renal cell cancer
7. Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
8. Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
9. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
10. Sequenztherapie des metastasierten Nierenzellkarzinoms
11. Gene expression profiling of hypoxic response in different models of senescent endothelial cells
12. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma
13. Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
14. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
15. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab
16. Risikoadaptierte Therapie des metastasierten Nierenzellkarzinoms
17. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component
18. Antitumor effect of axitinib combined with dopamine and PK-PD modeling in the treatment of human breast cancer xenograft
19. Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
20. Combined VEGF/PDGF inhibition using axitinib induces αSMA expression and a pro-fibrotic phenotype in human pericytes
21. Presurgical axitinib therapy increases fibrotic reactions within tumor thrombus in renal cell carcinoma with thrombus extending to the inferior vena cava
22. Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
23. Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
24. Promising response to axitinib rechallenge for metastatic renal cell carcinoma after progression on prior axitinib: report of two cases
25. Randomized phase II trial comparing axitinib with the combination of axitinib and lomustine in patients with recurrent glioblastoma
26. Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma
27. Avelumab: First Global Approval
28. 18F-FLT PET/CT imaging in patients with advanced solid malignancies treated with axitinib on an intermittent dosing regimen
29. Lack of effect of smoking status on axitinib pharmacokinetics in patients with non-small-cell lung cancer
30. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma
31. Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma
32. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells
33. Efficacy and safety of axitinib in elderly patients with metastatic renal cell carcinoma
34. Axitinib-induced proteinuria and efficacy in patients with metastatic renal cell carcinoma
35. Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Arterielle Hypertonie
36. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion
37. Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Gastrointestinale Nebenwirkungen
38. Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
39. Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der Urologie: Fatigue und Hypothyreose
40. A phase II study evaluating axitinib in patients with unresectable, recurrent or metastatic head and neck cancer
41. Presurgical treatment with axitinib in renal cell carcinoma patients with venous extension
42. Non-significant impact of proteinuria on renal function in Japanese patients with metastatic renal cell carcinoma treated with axitinib
43. Pharmacodynamic study of axitinib in patients with advanced malignancies assessed with 18F-3′deoxy-3′fluoro-l-thymidine positron emission tomography/computed tomography
44. Axitinib plasma pharmacokinetics and ethnic differences
45. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial
46. Effect of axitinib on the QT interval in healthy volunteers
47. Pharmacokinetics of single-agent axitinib across multiple solid tumor types
48. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses
49. Pembrolizumab: First Global Approval
50. Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.